YouTube video by Canadian Retro Things

Clinical study to evaluate NS002, the Company's investigational intranasal epinephrine powder, as a needle-free alternative to EpiPen® for patients experiencing anaphylaxis and will compare self-admin...

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

Rubin will stay through Sept. 18 for the handoff; Elmaliach brings more than 15 years of financial experience as Nasus advances NS002.

July 28, 2026 07:30 ETTEL AVIV, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus", “Nas ...

Gli appassionati di picchiaduro e arcade classici sanno quanto sia importante avere un controller che restituisca il feeling autentico delle sale giochi. Il controller Arcade NS002…

Label: Nomada Sounds Catalog: NS002 Released: 2025-11-20 Style: Organic House Bitrate: Flac+320kbps Tracklist: 01. Mother (Original Mix) (10:05) [center] [center] send.cm - flac send.cm - 320 kbps [/center]

TEL AVIV, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative i...

Reported Wednesday, Mar 25 - 9:25am EDT (TheFly subscription required to read more.)

Reported Monday, Mar 16 - 7:32am EDT (TheFly subscription required to read more.)

Reported Tuesday, Jan 20 - 8:19am EST (TheFly subscription required to read more.)

Reported Tuesday, Nov 18 - 9:30am EST (TheFly subscription required to read more.)

Reported Thursday, Nov 6 - 8:26am EST (TheFly subscription required to read more.)

Nasus Pharma (NYSE: NSRX) reported positive Phase 2 topline results for NS002, showing faster early epinephrine absorption versus EpiPen and consistent absorption under nasal allergic challenge. The company plans a pivotal study to start in Q4 2026 with a planned readout in Q1 2027, and believes results support a potential NDA filing.Nasus is advancing NS003 and NS004 toward first-in-human studies in H2 2026 and is advancing NS005. As of Dec 31, 2025, cash and equivalents were $4.3 million; R&D was $2.4M, G&A $2.7M, and net loss $5.9M. Shares outstanding: 9,015,383.

Interim results indicate NS002 demonstrated significantly faster absorption and higher peak epinephrine levels compared to EpiPen ® 91% of study participants achieved the 100 pg/ml plasma threshold at 5 minutes with NS002 compared to 67% with EpiPen ® NS002 was well-tolerated with no serious

Nasus Pharma (NYSE: NSRX) issued a 2025 shareholder letter outlining clinical and corporate milestones. The company completed an IPO in August 2025, raising $10 million in gross proceeds, and described progress advancing NS002, an investigational intranasal epinephrine powder based on its proprietary Nasax technology.Key 2025 developments include expanded collaboration agreements with Aptar, Health Canada authorization to start a Phase 2 trial, and dosing of the first patient in October 2025. Near-term milestones include an interim analysis expected early Q1 2026 and a topline Phase 2 readout planned for end of Q1 2026, with IND, pivotal, and pediatric study initiations targeted in Q3–Q4 2026.

BitMine (NYSE AMERICAN: BMNR) announced a registered direct offering to sell 5,217,715 common shares at $70.00 per share and warrants to purchase 10,435,430 shares at a $87.50 strike. The company expects aggregate gross proceeds of approximately $365.24 million from the equity sale, with potential additional proceeds of about $913 million if all warrants are exercised, for combined potential proceeds near $1.28 billion. The share price represents a roughly 14% premium to the September 19, 2025 close of $61.29. Warrants will be exercisable on issuance and expire March 22, 2027. Closing is expected on or about September 23, 2025.

Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or